Our colleagues on our sister blogsite Federal Securities Law Blog have been tracking new and updated SEC regulations that could impact on the businesses of our readers. The articles in their most recent eBook SEC Updates: Keeping Ahead of the Regulatory Curve (which you can download here ) discuss three important SEC regulatory changes: compensation committee rules, conflict minerals reporting and whether companies that use social media to communicate with investors are complying with Regulation Fair Disclosure.
"A thing of beauty" , as John Keats once wrote, may be "a joy forever", but works of art, whether they are sculptures, paintings, buildings, or books, do not last forever. Over time, delicate pigments fade, restoration or conservation attempts may go wrong, or objects of art may be attacked, such as the attack by Laszlo Toth on Michelangelo's Pieta or the more recent destruction of theBuddhas of Bamiyan by the Taliban in Afghanistan in 2001.
The main objective of the NANOFORART proposal is the development and experimentation of new nano-materials and responsive systems for the conservation and preservation of movable and immovable artworks.
While the progress in material science has generated sophisticated nanostructured materials, conservation of cultural heritage is still mainly based on traditional methods and conventional materials that often lack the necessary compatibility with the original artworks and a durable performance in responding to the changes of natural environment and man-made activities.
The main challenge of NANOFORART is the combination of sophisticated functional materials arising from the recent developments in nano-science/technology with innovative techniques in the restoration and preventive conservation of works of art, with unprecedented efficiency.
An earlier posting on this site discussed the use of nanomaterials to preserve and conserve artifacts found at archealogical excavation sites, the use of such nanomaterials to preserve works of art is a new development in this area.
Many of the greatest works of art have lasted for hundreds of years and have become part of the cultural heritage of all humanity. For example, Van Gogh's many paintings of Sunflowers, one of which is at the top of this posting, are as well known and admired in Asia or South America as they are in Europe. Let us hope that the use of nanomaterials can lead to the Mona Lisa. smiling her enigmatic smile for another 500 years.
With significant changes to law governing how the U.S. grants patents taking effect next month, Porter Wright recommends that all clients consider filing any contemplated patent applications by March 15. This includes filing non-provisional patent applications, and in some cases Patent Cooperation Treaty (PCT) patent applications, that are based upon any provisional or non-U.S. patent application filed since March 2012. Though there are some exceptions to this advice, waiting until after March 15 may be problematic.
In brief: For patent applications having any claim with an effective filing date after March 15, it will no longer be possible to overcome prior art by showing an earlier date of invention. Thus, the prior art for purposes of patentability will include: 1) third-party public disclosures of any kind, anywhere in the world, prior to your effective filing date; and 2) issued U.S. patents and published U.S. or PCT patent applications that were effectively filed before your effective filing date. In addition to not being able to "swear behind" a prior art reference by proving an earlier date of invention, the prior art date for patents and published patent applications may be as much as 18 months earlier than under current law because of foreign priority claims.
It is also important to note that inventors will not lose the benefit of any earlier provisional or non-U.S. patent application should they wait until after March 15 to file. Any claims that are adequately supported in the earlier filing will be entitled to that earlier filing date for purposes of patentability. However, if even one claim in the post-March 15 application is new (i.e., includes subject matter not disclosed in your earlier application) the new first-to-file rules will apply to all claims — and there will be no way to alter this scenario through actions such as deleting claims containing the new subject matter.
A Porter Wright Law Alert describes these patent law changes in greater detail.
The 113th Congress has begun it's first session and, as is the usual procedure at the start of a new Congress, new chairpersons have been selected for most of the House and Senate Committees. Among these new chairs is Representive Lamar S. Smith (R-TX-21st), Chair of the House Committee on Science, Space and Technology. Much of the legislation that has affected nanoindustry and the nanotech community has passed before this committee.
Rep. Smith as long been a supporter of the nanotech community, co-sponsoring such legislation as the "National Nanotechnology Initiative Amendments Act of 2009". and is a senior member of the Congressional Nanotechnology Caucus.
Along with a new committee chairperson, the subcommittees have also gotten new chairs. The Subcommittee on Research and Education, which "has legislative jurisdiction and general oversight and investigative authority on all matters relating to science policy and science education including: . . . research, development, and demonstration relating to nanoscience, nanoengineering, and nanotechnology", is now chaired by Rep. Larry Bucshon (R-IN-8th). Rep. Bucshon, first elected in the 2010 midterm elections, has not sponsored or co-sponsored much legislation and his positions on nanotechnology and nanoindustry are as yet unknown.
Legislation affecting either nanoindustry or the larger nanotech community has yet to be introduced in either the House or the Senate; such legislation may benefit from having Rep. Smith as Committee Chairperson.
Today's Federal Register carries a notice from the National Institute for Occupational Health and Safety (NIOSH) requesting information and comments regarding silver nanoparticles. NIOSH
has initiated an evaluation of the scientific data on silver nanoparticles
(AgNPs) to ascertain the potential health risks to workers and to
identify gaps in knowledge so that appropriate laboratory and field
research studies can be conducted. . . .
. . . gathering data to determine whether a
health risk to workers may exist from exposure to AgNPs and if specific
risk management guidance is needed to prevent exposure. . . .
Information is particularly needed for determining the relevance
of bile duct hyperplasia and hepatocellular necrosis observed in AgNP
exposed rats, as well as information on: (1) Sources of AgNP exposure,
(2) factors that influence worker's exposure, (3) in-place exposure
control measures (e.g., engineering controls) and work practices that
are effective in reducing worker exposures, and (4) appropriate
measurement methods and exposure metrics for characterizing workplace
exposures. . . .
Examples of requested
information include the following:
(1) Identification of industries or occupations in which exposures
to AgNPs may occur.
(2) Trends in the production and use of AgNPs.
(3) Description of work tasks and scenarios with a potential for
exposure to AgNPs.
(4) Workplace exposure measurement data in various types of
industries and jobs.
(5) Case reports or other health information demonstrating
potential health effects in workers exposed to AgNPs.
(6) Research findings from in vitro and in vivo toxicity studies,
including physical-chemical characterization of AgNPs.
(7) Information on control measures (e.g., engineering controls,
work practices, PPE) being taken to minimize worker exposure to AgNPs.
(8) Information on measurement methods and exposure metrics that
can be used to quantify worker exposure to AgNPs including information
on the limitations of those methods in quantifying exposures?
Information submitted my include "published and unpublished reports and research findings".
"All information received in response to this notice must include the agency name and docket number (CDC-2012-0014; NIOSH-260)". and may be submitted either online via Regulations.gov - instructions on how to submit are available on the website - or by mail to
NIOSH Docket Office,
Robert A. Taft Laboratories,
4676 Columbia Parkway, Cincinnati, OH 45226.
Comments and information submitted will be posted to the docket on Regulations.gov. The deadline for submitting either comments or information is February 19, 2013.
NIOSH has compiled a listing of relevant publications regarding AgNPS, "Evaluation of the Scientific Data on Silver Nanoparticles (AgNPS)" and will be posting that listing to the docket on Regulations.gov. Several studies of silver nanoparticles are listed as references in the notice and presumable compose the bulk of the listing. This posting will be updated when the list is available.
For further information please contact
Ralph Zumwalde, NIOSH,
Robert A. Taft Laboratories,
4676 Columbia Parkway, Cincinnati, Ohio 45226,
telephone (513) 533-8320
or Eileen Kuempel, telephone (513) 533-8363
"Evaluation of the Scientific Data on Silver Nanoparticles (AgNPS)" has been posted to the docket on Regulations.gov.
It's that time of year – crowded shopping centers, festive gatherings, and time with family both near and far.
For employers the holidays create increased risk of employer liability – which may result in legal problems for those that are unprepared. Members of our Labor and Employment practice publish the Employer Law Report, which today posted a timely eBook compiling the top five holiday headaches for employers. As many may find the topic of interest, we wanted to take a moment and share it with our readers as well.
The ebook complies the following posts:
· Avoiding Holiday Party Liability When the Office Santa Tries to Teach His Employees a Few"Reindeer Games"
· Being Inclusive Without Being A Grinch
· "Holiday Attire" Does Not Include "Beer Goggles"
· Holiday Pay and How Not to Get Scrooged by The FLSA
· What if Santa Was the One Who Got Run Over By a Reindeer
· Three FMLA Stocking Stuffers: How to Avoid a Big Lump of Coal (bonus)
As engineered nanoparticles (ENPs) become increasingly common in consumer products and the environment, concern over their possible effects on human health also rises. There is concern over the possible penetration of human skin by ENPs. "However, the evidence whether nanoparticles can infiltrate into underlying tissues is conflicting . . . clarification of the issue is essential. . .."
With this in mind, Christopher. S.J. Campbell of Mango Business Solutions, L. Roderigo Contreras-Rojas, M. Begona Delgado-Charro, and Richard H. Guy, of the University of Bath Department of Pharmacy & Pharmacology have recently published a study "Objective assessment of nanoparticle disposition in mammalian skin after topical exposure" in the Journal of Controlled Release discussin the results of their attempts to measure the extent and depth that ENPs are able to penetrate the skin, in the case of this study the specially cleaned and prepared skin of a pig.
Following exposure to ENPs, the skin samples were examined using a laser scanning confocal microscope. The reported results indicate that ENPs did not fully penetrate the skin, but only penetrated where a crease or a crack in the skin was present.
The authors note and warn about the limited nature of their research:
It should be emphasised that this research has clearly not been able to make a systematic evaluation of nanoparticle disposition on the skin for the entire spectrum of particle properties, including shape and charge. . . .the observations and their analysis cannot explain, with any degree of certainty, why others have reported nanoparticle uptake into living skin layers following their topical application . . . . While speculative alternatives might be proposed, such as accidental contamination on sectioning, or invisible flaws in skin integrity (across which, for example, a very small quantum dot of a few nanometres diameter might be able to travel), complete understanding will only be possible with further, scrupulously controlled experiments coupled with objective data analysis and interpretation.
According to a recent article in the Sydney Morning Herald, the study has been criticized by Dr. Gregory Crocetti of Friends of the Earth Australia and Professor Brian Gulson of the Department of Environment and Geography at Macquarie University.
The study is not the definative work in this area and the authors have noted its limitations; it is one more contribution to a growing body of scientific literature on the subject of nanoparticles and human health.
In a notice that appeared in last Thursday's Federal Register, the National Nanotechnology Coordination Office (NNCO), announced that it would be hosting a webinar on Nano.gov on Thursday 09/20/2012, from 12:15 until 1PM. " NNCO is seeking public comment and recommendations on potential updates to, improvements on, and opportunities for public engagement through Nano.gov."
The webinar will consist of two parts. Part 1, the first 20 minutes of the webinar, will be spent on short presentations by the moderator and four panelists:
Marlowe Epstein-Newman, National Nanotechnology Coordination Office (NNCO)—Marlowe is the Communications Director at NNCO and was the Project Manager for the first Nano.gov redesign in 2011. She manages the content on Nano.gov as well as the NNI’s social media presence.
Carl Batt, Cornell University—Carl is a Food Science professor with ties to National Science Foundation as a regularly consulted expert. Carl recently collaborated with the National Nanotechnology Infrastructure Network and Walt Disney World to create a permanent nanotechnology exhibit at Epcot Center.
Joshua A, Chamot, National Science Foundation (NSF)—Josh is a public affairs specialist in NSF's Office of Legislative and Public Affairs. As a seasoned public affairs professional, he provides a unique perspective on media, public relations, and outreach tactics from a Federal Government perspective. Josh works in a variety of media to bring science stories to the public.
Mary Ann Latko, American Industrial Hygiene Association(AIHA)—Mary Ann is a Managing Director at AIHA. She represents workers across manufacturing sectors and is well-versed in enivironment, health, and safety (EHS) and regulatory issues, often working closely with the National Institute for Occupational Safety and Health (NIOSH).
Nazhin Beiramee, OMNI Studios—Nazhin is a web designer who has worked on Nano.gov as well as other .govs including the the Food and Drug Administration, the National Institutes of Health, and the National Cancer Institute.
The remaining portion of the webinar will be a Q&A session, with questions submitted by the audience. Questions and comments should be focused on
How is Nano.gov useful to you and your stakeholders/colleagues/peers?
What do you like on Nano.gov? Which pages are most useful to you? Why?
What would you like to see improved? Are there pages you don’t understand? Confusing information? Poor layout? Difficult to use?
Are there pages that you feel are missing from Nano.gov? What other types of pages would you like to see? What information would you like to find on Nano.gov that isn’t currently there?
Are there similar websites that present information in a way that you find more useful, exciting, attractive or user-friendly?
The NNCO will begin accepting questions and comments via email (email@example.com) and Twitter (@NNInanonews) 24 hours prior to the event, until the close of the webinar at 1pm on September 20. These will be read and addressed during the live event. The NNCO reserves the right to group similar questions and to address only those questions and comments germane to the topic.
Registration for the webinar is required and is now open.
Rice University, located in the city of Houston, Texas, is observing it's 100th anniversary in October of this year, and many of the Texan members of the US House of Representives have made congratulatory remarks on the floor of the House or have inserted them in the Congressional Record Extension of Remarks.In their remarks, Rep. John Culbertson (R-7th) and Rep. K. Michael Conway (R-17th) paid particular attention to Rice's role in the nanotech world. Their remarks are below.
RICE UNIVERSITY'S 100TH ANNIVERSARY -- (House of Representatives - July 11, 2012) [Page: H4790]
(Mr. CULBERSON asked and was given permission to address the House for 1 minute and to revise and extend his remarks.)
Mr. CULBERSON. Madam Speaker, I have the singular privilege of representing Rice University, and I join my colleagues from Houston in recognizing and congratulating them on their 100th anniversary this year.
Rice has consistently been ranked as one of the Nation's greatest universities and recognized by U.S. News & World Report as among the Nation's top 20 universities. And they've consistently ranked in the top 50 universities in the world.
Rice University researchers are pioneers in a broad spectrum of fields, including space, energy, and my personal passion, nanotechnology. Nanotechnology is an absolute game-changer, revolutionizing everything that we will touch and see in the 21st century. Rice University is the birthplace of nanotechnology research.
Nanotechnology holds incredible potential for everything from curing cancer to improving the storage and transmission of electricity and moving electricity in ways that we cannot even imagine today, allowing us to miniaturize devices. Multistage nanoparticles will allow the delivery of cancer-curing drugs to individual structures within cells, allowing scientists to identify diseases at the cellular level, things that could not have been possible without the groundbreaking work at Rice University.
I congratulate them on their 100th anniversary today.
RICE UNIVERSITY 100TH BIRTHDAY -- HON. K. MICHAEL CONAWAY (Extensions of Remarks - July 11, 2012) [Page: E1235]
HON. K. MICHAEL CONAWAY OF TEXAS IN THE HOUSE OF REPRESENTATIVES Wednesday, July 11, 2012
Mr. CONAWAY. Mr. Speaker, I rise today to congratulate Rice University on its 100th birthday. For over a century it has stood as one of the premier educational institutions in the world.
Over the past 100 years, Rice University's name has come to be synonymous with excellence. The institution consistently ranks among the top 20 national universities in the U.S. News & World Report and holds many other marks of excellence.
For example, in 2010 Rice University was ranked No. 1 worldwide in materials science research. In 2011, the Carnegie Foundation gave the university top classifications for ``very high research activity'' and ``comprehensive doctoral program''.
While this is an amazing accomplishment, Rice's work is more than just a statistic--it has changed the world we live in. The research performed by the university has proved groundbreaking on several fronts, most notably the discovery of ``buckyballs.'' The discovery launched the field of Nanotechnology which has led directly to advances many fields, including medicine, technology, energy, defense, and transportation. Nanotechnology is already playing a powerful role in the lives of Americans, from its capacity to help find cures to deadly diseases to reducing the cost and extending the lifespan of consumer products like clothes and cars.
Rice's School of Business, Architecture, Engineering, Social Sciences, Music, Humanities, Institute of Public Policy, and the Alliance of Technology and Entrepreneurship all hold similar national standing.
Not only is Rice University a heavyweight contender in academic and research fields, the university also maintains a noteworthy athletic department. For 17 consecutive years, Rice has produced a NCAA conference championship team--another outstanding accomplishment.
Again, congratulations to Rice University on its 100th birthday. Rice University's devoted faculty and student body have continually endeavored for excellence, and as a result Texans, Americans, and people all over our world have benefited.
As many readers of this blog are by now aware, the Supreme Court today issued its much anticipated opinion in National Federation of Business et al v. Sebelius, regarding the constitutionality of the Patient Protection and Affordable Health Care Act (PL 111-148), more commonly refered to as "Obamacare". Because of the importance of this decision, we're attaching a link to another blog site maintained by Porter Wright Morris & Arthur LLP, "Employee Benefits Law Report", and to an entry , "Health Care Reform Survives Supreme Court Scrutiny - But Not Entirely Intact", authored by Rich McHugh, a partner in the Porter Wright DC office. Rich's practice focuses on employee benefits. A link to the decision is embedded within the article.
Several studies of possible toxic effects of quantum dots on humans have been done using cell cultures in petri dishes or rodents, usually white lab rats. But lab rats are related to humans only in that both are mammals.
In a recently published letter in Nature Nanotechnology,"A pilot study in non-human primates shows no adverse response to intravenous injection of quantum dots", published online 05/20/2012, Ling Ye and other authors based at PLA General Hospital in Beijing, SUNY-Buffalo, Nanyang Technological University, and Changchun University of Science and Technology, report the results of experiments where quantum dots where injected into male rhesus monkeys. Rhesus monkeys were chosen for this experiment since they are genetically and physiologically closer to humans than rodents and are less endangered than chimpanzees.
The authors report that the rhesus monkeys did not exhibit any ill effects from the injections:
A complete blood count (cbc) was performed at regular intervals and the results did not suggest any acute toxicity.
After 90 days, the study did find that quantum dots had accumulated in the liver, spleen, and kidneys and in lesser amounts in the heart, lungs, and other organs. Examinations of tissues from these organs found no abnormalities.
In conclusion, rhesus macaques intravenously injected with ~ 25 mg of a cadmium based quantum dot formulation survived without any evidence of toxicity. All measured biochemical markers were in the normal range. . . .However, given the persistence of elevated cadmium and selenium levels in organs after three months, longer term studies will be required to determine the ultimate fate of these heavy metals and any ill effects arising due to their presence. All data obtained in this pilot study suggest that the phospholipid micelle encapsulated quantum dot formulation has very low tosicity on the timescale considered. This suggests a potential role for quantum dots in human clinical applications, such as image guided surgery for tumour removal, where the advantages provided for quantum dots can outweigh the potential risk associated with accumulation of their constituent elements in the body.
As nanoparticles become more commonly used in everyday products it becomes increasingly important to understand " nanoparticle aggregation in the aqueous environment . . . for assessing the fate, transport and toxicity of nanomaterials". In an effort to increase the body of scientific knowledge in this area, Dongxu Zhou, Samuel W. Bennett, and Arturo A. Keller, all of the University of California Santa Barbara Bren School of Environmental Science and Management, in an article published on the PLOS One website "report for the first time . . . temperature variations can cause either agglomeration or disagglomeration . . . depending on the heating and cooling paths. This finding is very relevant . . . , since it indicates that ambient temperature change, constantly occurring in open waters, can alter nanoparticle mobility." Following studies cited in the article's references, the authors define aggregates as "particle clusters bound by irreversible chemical bonds", while agglomerates are "clusters" held together by weak physical interactions. " Once released in the environment, nanoparticles will very likely exist as agglomerated aggregates, i.e. aggregate clusters that have weaker bonds between them. "
In experiments on clusters of three types of metallic oxides - titanium dioxide, zinc oxide, and cerium oxide - lead the authors to conclude
. . . that in open water these soft (weakly bonded) agglomerates can be disagglomerated by common environmental stimuli, such as exposure to sunlight or an increase in temperature from diurnal variations. Although not evaluated, it is likely that mechanical shocks may also result in temporary disagglomeration. The released aggregates can be much more mobile and bioavailable while the stimuli is present. Although in our experimental setting we observe reagglomeration once the stimuli are removed, in the environment it may be that the probability of interacting with another nanoparticle aggregate is much lower. . . . The effect of disagglomeration on toxicity has not been considered, or systematically evaluated. This phenomenon warrants attention since it is likely that these metal oxide nanoparticles will experience these natural stimuli during their transport in the environment.
Prior to adjourning for the Memorial Say recess, the Senate, on 05/24/2012, by a vote of 96-1, passed S. 3187, the "Food and Drug Administration Safety and Innovation Act", " To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs and medical devices, to establish user-fee programs for generic drugs and biosimilars, and for other purposes", after previously adopting an amendment in the nature of a substitute- an amendment in the nature of a substitute strips all of the language of a bill following the enacting clause and replaces it with new language - offered by Senator Tom Harkin (D-Iowa). Included as part of the language of the amendment was Title XI - Other Provisions, Subtitle C- Misc. Provisions, Section 1133, "Nanotechnology Regulatory Science Program":
SEC. 1133. NANOTECHNOLOGY REGULATORY SCIENCE PROGRAM.
(a) In General- Chapter X (21 U.S.C. 391 et seq.) is amended by adding at the end the following:
`SEC. 1013. NANOTECHNOLOGY REGULATORY SCIENCE PROGRAM.
`(a) In General- Not later than 180 days after the date of enactment of the Food and Drug Administration Safety and Innovation Act, the Secretary, in consultation as appropriate with the Secretary of Agriculture, shall establish within the Food and Drug Administration a Nanotechnology Regulatory Science Program (referred to in this section as the `program') to enhance scientific knowledge regarding nanomaterials included or intended for inclusion in products regulated under this Act or other statutes administered by the Food and Drug Administration, to address issues relevant to the regulation of those products, including the potential toxicology of such materials, the effects of such materials on biological systems, and interaction of such materials with biological systems.
`(b) Program Purposes- The purposes of the program established under subsection (a) may include--
`(1) assessing scientific literature and data on general nanomaterials interactions with biological systems and on specific nanomaterials of concern to the Food and Drug Administration;
`(2) in cooperation with other Federal agencies, developing and organizing information using databases and models that will facilitate the identification of generalized principles and characteristics regarding the behavior of classes of nanomaterials with biological systems;
`(3) promoting Food and Drug Administration programs and participate in collaborative efforts, to further the understanding of the science of novel properties of nanomaterials that might contribute to toxicity;
(4) promoting and participating in collaborative efforts to further the understanding of measurement and detection methods for nanomaterials;
(5) collecting, synthesizing, interpreting, and disseminating scientific information and data related to the interactions of nanomaterials with biological systems;
(6) building scientific expertise on nanomaterials within the Food and Drug Administration, including field and laboratory expertise, for monitoring the production and presence of nanomaterials in domestic and imported products regulated under this Act;
(7) ensuring ongoing training, as well as dissemination of new information within the centers of the Food and Drug Administration, and more broadly across the Food and Drug Administration, to ensure timely, informed consideration of the most current science pertaining to nanomaterials;
(8) encouraging the Food and Drug Administration to participate in international and national consensus standards activities pertaining to nanomaterials; and
(9) carrying out other activities that the Secretary determines are necessary and consistent with the purposes described in paragraphs (1) through (8).
(c) Program Administration-
(1) DESIGNATED INDIVIDUAL- In carrying out the program under this section, the Secretary, acting through the Commissioner of Food and Drugs, may designate an appropriately qualified individual who shall supervise the planning, management, and coordination of the program.
(2) DUTIES- The duties of the individual designated under paragraph (1) may include--
(A) developing a detailed strategic plan for achieving specific short- and long-term technical goals for the program;
(B) coordinating and integrating the strategic plan with activities by the Food and Drug Administration and other departments and agencies participating in the National Nanotechnology Initiative; and
(C) developing Food and Drug Administration programs, contracts, memoranda of agreement, joint funding agreements, and other cooperative arrangements necessary for meeting the long-term challenges and achieving the specific technical goals of the program.
(d) Report- Not later than March 15, 2015, the Secretary shall publish on the Internet Web site of the Food and Drug Administration a report on the program carried out under this section. Such report shall include--
(1) a review of the specific short- and long-term goals of the program;
(2) an assessment of current and proposed funding levels for the program, including an assessment of the adequacy of such funding levels to support program activities; and
(3) a review of the coordination of activities under the program with other departments and agencies participating in the National Nanotechnology Initiative.
(e) Effect of Section- Nothing in this section shall affect the authority of the Secretary under any other provision of this Act or other statutes administered by the Food and Drug Administration.'.
(b) Effective Date; Sunset- The Nanotechnology Regulatory Science Program authorized under section 1013 of the Federal Food, Drug, and Cosmetic Act (as added by subsection (a)) shall take effect on October 1, 2012, or the date of the enactment of this Act, whichever is later. Such Program shall cease to be effective October 1, 2017.
Except for some stylistic changes and the removal of a subparagraph on appropriations, Sect. 1133 is the language of S. 1662 , the "Nanotechnology Regulatory Science Act of 2011", introduced on 10/06/2011 by Senator Mark Pryor (D-Arkansas) andSenator Ben Cardin (D-Maryland) and subsequently assigned to the Senate Committee on Health, Education, Labor and Pensions . No hearings were ever held on the bill nor was it ever reported out of committee.
During floor debates on S. 3187, Senator Cardin urged his felllow Senators to support and pass S. 3187, focusing on the language of Sec. 1134:
Mr. CARDIN. Madam President, I rise to discuss the FDA Safety and Innovation Act, the bill now under consideration here in the Senate.. . .
I express my appreciation to Senator Pryor for his leadership on nanotechnology. I am pleased to join him in this effort and am hopeful that the language we have sponsored can be included in this bill.
Nanotechnology has become increasingly indispensible in our daily lives--everything from cellphones and MP3 players, to packaging of our snack foods, to cancer treatments in development employ the use of nanotechnology.
As this burgeoning technology continues to power more of our consumer products and drive job creation in America, it is essential that we fully assess, understand, and address any risks that it may pose to safety, public health and our environment.
By soundly assessing the safety of nanotechnology and developing best practices, the Nanotechnology Regulatory Science Act of 2011 will further job creation, public safety and growth in the industry.
Our bill would establish a program within the FDA to assess the health and safety implications of using nanotechnology in everyday products, and develop best practices for companies using nanotechnology. This new program would bring more highly-skilled research jobs to Maryland.
FDA's laboratories and research facilities at its consolidated headquarters are ideally suited to conduct the scientific studies required under the bill.
The USDA's Beltsville Agricultural Research Center, BARC, is similarly equipped to provide innovative scientific technology, training, methods development, and technical expertise to improve public health. . . . .
I also will mention one other issue: nanotechnology. I congratulate Senator Pryor for his leadership in this area. Programs at FDA to access health safety facts and using nanotechnology in everyday products is something we need to do. This legislation advances that. I point out that I am proud that the lab facilities at the FDA are fully capable of dealing with the challenges presented by nanotechnology. This legislation acknowledges that.
We also, in Maryland, are proud of the Beltsville Agricultural Research Center, which will advance nanotechnology and the impact it has on everyday products and safety. Those issues will be addressed also by the underlying bill. We very much appreciate the leadership of the committee.
On 05/30/2012, the House, under a suspension of the rules, passed H.R. 5651, the "Food and Drug Administration Reform Act of 2012". H.R. 5651 differs substantially from S. 3187; among these differences, H.R. 5651 contains no provisions regarding nanotechnology. These differences in language mean that a Conference Committee will be appointed to write a version of the two bills that should be adopted by both the Senate and the House. Although such a committee has not been appointed as of this date, one is expected to be formed soon. As with other legislation affecting nanotechnology we will monitor S.3187 and H.R. 5651 and update this site accordingly.
The possible presence of nanoparticles in food has, for the last few years, been a controversial topic, focusing usually on the possible toxic effects of manufactured carbon nanoparticles (MCNs) on human health. A recently published article by members of the Departments of Chemistry and Biotechnology at the Indian Institute of Technology Guwahati, "Presence of Amorphous Carbon Nanoparticles in Food Caramels", looked at a different aspect of the contoversy, naturally produced carbon nanoparticles. As the authors point out, naturally produced carbon nanoparticles (CNPs) have possibly been present in various types of food for thousands of years and offer the possibility of being used as vehicles for the delivery of medications within the human body.
In their study, Prof. Arun Chattopadhyay and colleagues tested "regular carbohydrate based food caramels, such as bread, jaggery, corn flakes, and biscuits . . . . where the preparation of food maily involves heating the starting ingredients in the absence of water, leading to the formation of caramels", for the presence of CNPs, which were detected. The CNPs were not of a uniform size, as would be expected with MCNs but were of various sizes, "indicating temperature dependent formation". More importantly
These caramels containing CNPs have been consumed by human beings with no know toxicity and thus it can be considered to have no or minimum risk on human health and be used as a safe nanomaterial.
All of these are foods that, as the authors note, "have been consumed by humans for centuries, and thus they can be considered as safe" for use in "various biological applications", including, as mentioned above, the delivery of medications to specific sites within the human body, such as tumors,
European Plastics News posted an article on it's site last week,("Graphene developers seek routes out of the lab"), focusing on challenges to and progress in the commercialization of graphene, specifically its "potential as a mutlifunctional reinforcement in composites".
Among the challenges the article raises are:
1) Entangling of 3D carbon nanotubes (CNTS) bundles
2) Individual graphite sheets restacking themselves
3) Handling of such shets during transportation to processing facilities
4) Reduction of costs of production and transportation
5) A need to develop standard operating procedures for potential health hazards
While these challenges may seem daunting, the success of three companies - Vorbeck Materials of Maryland,Cabot Corporation of Massachusetts, and Thomas Swan & Co., based in the United Kingdom - are highlighted.
The article also discusses the ongoing support of the European Commission (EC) and the UK's government of research in graphene and how to commercialize it.:
The European Commission is planning to channel €1bn over 10 years into co-ordinated graphene research and commercialisation. The UK government has announced it wants to spend another £50m (€60.7m) to keep the UK at the forefront of graphene research, with the University of Manchester set to host a national institute of graphene research. Commercialisation of graphene by this route could arrive by late 2012.
Converted in US dollars, the EC will be spending $1.278 billion and the UK $78.153 million.